MX2015015553A - Composicion farmceutica de dosis baja. - Google Patents

Composicion farmceutica de dosis baja.

Info

Publication number
MX2015015553A
MX2015015553A MX2015015553A MX2015015553A MX2015015553A MX 2015015553 A MX2015015553 A MX 2015015553A MX 2015015553 A MX2015015553 A MX 2015015553A MX 2015015553 A MX2015015553 A MX 2015015553A MX 2015015553 A MX2015015553 A MX 2015015553A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
deferasirox
low dose
dose pharmaceutical
composition comprises
Prior art date
Application number
MX2015015553A
Other languages
English (en)
Inventor
Geena Malhotra
Shrinivas Madhukar Purandare
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of MX2015015553A publication Critical patent/MX2015015553A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención proporciona una composición farmacéutica de dosis baja que comprende deferasirox o un derivado farmacéuticamente aceptable del mismo y uno o más excipientes farmacéuticamente aceptables. Una dosis unitaria de la composición farmacéutica comprende desde aproximadamente 50 mg a aproximadamente 100 mg de deferasirox, desde aproximadamente 150 mg a aproximadamente 200 mg de deferasirox o desde aproximadamente 260 mg hasta aproximadamente 350 mg de deferasirox. La composición farmacéutica de la presente invención, en la que la composición farmacéutica comprende deferasirox, puede usarse para tratar sobre carga de hierro crónica o para tratar toxicidad por plomo. La composición farmacéutica de la presente invención, en la que la composición farmacéutica comprende deferasirox y deferiprona, puede usarse para tratar toxicidad por plomo. Esta invención también proporciona un procedimiento para preparar la composición farmacéutica de dosis baja, comprendiendo el procedimiento: disolver o adsorber o combinar deferasirox y al menos un excipiente para producir una dispersión de deferasirox; y procesar la dispersión para producir una forma de dosificación deseada.
MX2015015553A 2013-05-10 2014-05-08 Composicion farmceutica de dosis baja. MX2015015553A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1696MU2013 IN2013MU01696A (es) 2013-05-10 2014-05-08
PCT/GB2014/051400 WO2014181108A1 (en) 2013-05-10 2014-05-08 Low dose pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2015015553A true MX2015015553A (es) 2016-06-17

Family

ID=50979804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015553A MX2015015553A (es) 2013-05-10 2014-05-08 Composicion farmceutica de dosis baja.

Country Status (18)

Country Link
US (4) US20160120847A1 (es)
EP (1) EP2994131A1 (es)
JP (1) JP2016518398A (es)
CN (1) CN105377256A (es)
AP (1) AP2015008875A0 (es)
AU (1) AU2014264421A1 (es)
BR (1) BR112015028257A2 (es)
CA (1) CA2911671A1 (es)
EC (1) ECSP15051434A (es)
HK (1) HK1215191A1 (es)
IN (1) IN2013MU01696A (es)
MX (1) MX2015015553A (es)
PE (1) PE20151934A1 (es)
PH (1) PH12015502557A1 (es)
RU (1) RU2015149544A (es)
SG (1) SG11201509308TA (es)
WO (1) WO2014181108A1 (es)
ZA (1) ZA201403276B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3310354A4 (en) * 2015-06-17 2018-12-12 Dispersol Technologies, LLC Improved formulations of deferasirox and methods of making the same
RU2616267C1 (ru) * 2016-01-25 2017-04-13 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма индинавира немедленного высвобождения и способ ее получения
US20190091204A1 (en) * 2016-03-17 2019-03-28 Lupin Limited Compositions of deferasirox
CN105853367B (zh) * 2016-05-10 2019-07-12 广州加德恩医药有限公司 地拉罗司固体分散体的制备方法及其药物制剂
WO2018007956A1 (en) * 2016-07-05 2018-01-11 Jubilant Generics Limited Immediate release pharmaceutical composition of iron chelating agents
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
EP3639854A4 (en) 2017-06-16 2021-03-03 The Doshisha MTOR INHIBITIVE MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES AND USE THEREOF
US20200121652A1 (en) * 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
CN114533689A (zh) * 2017-10-25 2022-05-27 奇斯药制品公司 延迟释放去铁酮片剂及其使用方法
CN109646423A (zh) * 2018-12-03 2019-04-19 泓博元生命科技（深圳）有限公司 含nadh的生物高分子纳米球及其制备方法与应用
CN115400088B (zh) * 2022-09-06 2023-07-07 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
GB0408078D0 (en) 2004-04-08 2004-05-12 Novartis Ag Organic compounds
KR20080056225A (ko) 2005-10-19 2008-06-20 노파르티스 아게 데페라시록스를 포함하는 분산성 정제
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
WO2009067557A1 (en) 2007-11-19 2009-05-28 Teva Pharmaceutical Industries Ltd. Deferasirox pharmaceutical compositions
WO2010035282A1 (en) 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox
BR112013007276A2 (pt) 2010-10-01 2016-06-14 Cipla Ltd composição farmacêutica, processo para preparar uma composição farmacêutica, uso da coposição farmacêutica e método para tratar sobrecarga crônica de ferro
WO2013041730A1 (en) * 2011-09-23 2013-03-28 Universität Stuttgart Please note that the status of the person identified in Box 1 changed from Applicant for all designated States except US to Applicant for all designated States. Serum half-life extension using immunoglobulin binding domains

Also Published As

Publication number Publication date
US20170312254A1 (en) 2017-11-02
WO2014181108A1 (en) 2014-11-13
CN105377256A (zh) 2016-03-02
BR112015028257A2 (pt) 2017-07-25
IN2013MU01696A (es) 2015-06-26
ECSP15051434A (es) 2017-05-31
PE20151934A1 (es) 2015-12-26
AP2015008875A0 (en) 2015-11-30
US20160120847A1 (en) 2016-05-05
SG11201509308TA (en) 2015-12-30
CA2911671A1 (en) 2014-11-13
EP2994131A1 (en) 2016-03-16
PH12015502557A1 (en) 2016-02-22
ZA201403276B (en) 2015-07-29
US20160158202A1 (en) 2016-06-09
RU2015149544A (ru) 2017-06-16
HK1215191A1 (zh) 2016-08-19
AU2014264421A1 (en) 2015-12-03
JP2016518398A (ja) 2016-06-23
US20170095453A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
PH12015502557A1 (en) Low dose pharmaceutical composition
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
MY200608A (en) Hiv inhibitor compounds
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
PH12020550256A1 (en) 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
EP3895717A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING WEISSELLA CIBARIA WIKIM28 AS ACTIVE SUBSTANCE
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
PH12019501896A1 (en) Therapeutic dendrimers
MX2017010280A (es) Complejos de acetato de abiraterona, proceso para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
MX2016009332A (es) Conjugado de farmaco citotoxico-ligando, metodo de preparacion del mismo y uso del mismo.
PH12019501955A1 (en) Tri-cycle compound and applications thereof
IN2014MU00303A (es)
PH12016502246A1 (en) Carboxamide derivatives
MX2020012989A (es) Agente terapeutico para la fibrosis.
PH12019500043A1 (en) Novel benzenesulfonamide compositions for treatment of malignant pleural effusions
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
MX2017013281A (es) Metodos para tratar transtornos del almacenamiento lisosomal.
MX2019002149A (es) Metodo para el tratamiento de prurito y/o comezon.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
EA202091169A1 (ru) Применяемые в качестве ингибиторов iap миметики smac и их применение
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
EA038580B9 (ru) Агонист fxr, представляющий собой производное стероидов